IL225695A0 - תכשיר רוקחי המכיל בלסלאזיד או סודיום בלסלאזיד לשימוש בטיפול במחלות דרכי העיכול - Google Patents

תכשיר רוקחי המכיל בלסלאזיד או סודיום בלסלאזיד לשימוש בטיפול במחלות דרכי העיכול

Info

Publication number
IL225695A0
IL225695A0 IL225695A IL22569513A IL225695A0 IL 225695 A0 IL225695 A0 IL 225695A0 IL 225695 A IL225695 A IL 225695A IL 22569513 A IL22569513 A IL 22569513A IL 225695 A0 IL225695 A0 IL 225695A0
Authority
IL
Israel
Prior art keywords
balsalazide
pharmaceutical preparation
gastrointestinal disease
treating gastrointestinal
disodium
Prior art date
Application number
IL225695A
Other languages
English (en)
Original Assignee
Salix Pharmaceuticals Inc
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Inc, Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Inc
Publication of IL225695A0 publication Critical patent/IL225695A0/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL225695A 2005-08-24 2013-04-11 תכשיר רוקחי המכיל בלסלאזיד או סודיום בלסלאזיד לשימוש בטיפול במחלות דרכי העיכול IL225695A0 (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71130005P 2005-08-24 2005-08-24
PCT/US2006/033255 WO2007025146A2 (en) 2005-08-24 2006-08-24 Balsalazide formulations and manufacture and use thereof

Publications (1)

Publication Number Publication Date
IL225695A0 true IL225695A0 (he) 2013-06-27

Family

ID=37772439

Family Applications (2)

Application Number Title Priority Date Filing Date
IL189104A IL189104A (he) 2005-08-24 2008-01-29 תכשיר רוקחי המכיל בלסלאזיד או סודיום בלסלאזיד לשימוש בטיפול במחלות דרכי העיכול.
IL225695A IL225695A0 (he) 2005-08-24 2013-04-11 תכשיר רוקחי המכיל בלסלאזיד או סודיום בלסלאזיד לשימוש בטיפול במחלות דרכי העיכול

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL189104A IL189104A (he) 2005-08-24 2008-01-29 תכשיר רוקחי המכיל בלסלאזיד או סודיום בלסלאזיד לשימוש בטיפול במחלות דרכי העיכול.

Country Status (11)

Country Link
US (2) US20090252788A1 (he)
EP (3) EP2586427A3 (he)
JP (4) JP2009506067A (he)
CN (4) CN105267226A (he)
AU (1) AU2006282865B2 (he)
BR (1) BRPI0615195A8 (he)
CA (2) CA2816276A1 (he)
IL (2) IL189104A (he)
MX (1) MX2008002283A (he)
NZ (3) NZ565974A (he)
WO (1) WO2007025146A2 (he)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE554752T1 (de) 2004-02-06 2012-05-15 Pharmatel R & D Pty Ltd As Trustee For The Pharmatel R & D Trust Verwendung von aminosalicylaten beim reizdarmsyndrom mit durchfall als vorherrschendem symptom
US20080306029A1 (en) * 2004-05-28 2008-12-11 Salix Pharmaceuticals, Inc. Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
NZ565974A (en) * 2005-08-24 2012-07-27 Salix Pharmaceuticals Ltd Balsalazide formulations and manufacture and use thereof
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
AU2013228061B2 (en) * 2006-11-03 2015-11-26 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US9012580B2 (en) 2008-02-15 2015-04-21 Daikin Industries, Ltd. Tetrafluoroethylene/hexafluoropropylene copolymer and the production method thereof, and electrical wire
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
BR122014009845A2 (pt) 2010-04-26 2015-12-29 Salix Pharmaceuticals Ltd usos de balsalazida para preparação de composição farmacêutica para tratamento de distúrbio gastrointestinal e induzir remissão clínica de colite ulcerativa em indivíduos do sexo masculino, bem como para diminuir o escore de mmdai e cicatrização da mucosa em indivíduos do sexo masculino com colite ulcerativa
CN104546949A (zh) * 2015-01-19 2015-04-29 天津市宝坻区人民医院 一种治疗溃疡性结肠炎改进型复合药物配方
US20200405673A1 (en) * 2019-06-25 2020-12-31 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
US4298595A (en) * 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
WO1981002671A1 (en) * 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
EP0039306B1 (de) * 1980-03-28 1984-01-11 Ciba-Geigy Ag Neue Azofarbstoffe, Verfahren zu deren Herstellung und deren Verwendung
US4412922A (en) * 1980-07-02 1983-11-01 Abcor, Inc. Positive-charged ultrafiltration membrane for the separation of cathodic/electrodeposition-paint compositions
US4412992A (en) * 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4562024A (en) * 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
SE8405924L (sv) * 1984-11-23 1986-05-24 Pharmacia Ab Nya azoforeningar
US4781925A (en) * 1986-03-06 1988-11-01 American Home Products Corporation Calcium supplement compressed tablets
US5374430A (en) * 1986-09-18 1994-12-20 London School Of Pharmacy Pharmaceutical formulation
US5196205A (en) * 1987-10-12 1993-03-23 Borody Thomas J Method for treatment of gastro intestinal disorders
US5064637A (en) * 1989-05-30 1991-11-12 Board Of Regents, The University Of Texas System Substituted sulfonamide derivatives which inhibit allergic reactions
US5095073A (en) * 1990-03-02 1992-03-10 Exxon Research And Engineering Company Water soluble rigid rod sulfonated aromatic polyamide
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
DE9321574U1 (de) * 1992-03-11 2000-06-29 Asta Medica Ag Tabletten, Granulate und Pellets mit hohem Gehalt an Wirkstoffen für hochkonzentrierte, feste Darreichungsformen
US5498608A (en) 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
JPH08169847A (ja) * 1994-12-16 1996-07-02 Morishita Roussel Kk 固形製剤
US5905073A (en) * 1995-01-06 1999-05-18 Salix Pharmaceuticals, Inc. Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
SE9700934D0 (sv) * 1997-03-14 1997-03-14 Astra Ab New formulation
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
DK0971735T3 (da) * 1997-04-01 2008-07-07 Borody Thomas J Fremgangsmåder og præparater til behandling af inflammatorisk tarmsygdom
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
US6144381A (en) * 1997-05-14 2000-11-07 International Business Machines Corporation Systems, methods and computer program products for compass navigation of avatars in three dimensional worlds
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US5927500A (en) * 1998-06-09 1999-07-27 Milliken & Company Pharmaceutical containment package
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
IL140905A0 (en) * 1998-07-20 2002-02-10 Smithkline Beecham Corp Bioenhanced formulations comprising eprosartan in oral solid dosage form
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US20030138399A1 (en) * 1999-05-14 2003-07-24 Anton Peter A. Anti-inflammatory therapy for inflammatory mediated infection
CA2420576C (en) * 2000-08-29 2005-06-14 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
ATE460394T1 (de) * 2000-08-29 2010-03-15 Biocon Ltd 5-asa-derivate mit entzündungshemmender und antibiotischer wirkung und verfahren zur behandlung von krankheiten mit diesen derivaten
US6562871B1 (en) * 2000-11-06 2003-05-13 Boehringer Ingelheim Pharmaceuticals, Inc. Dry granulation of pharmaceutical formulation comprising mexiletine
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
WO2003011117A2 (en) * 2001-07-31 2003-02-13 The General Hospital Corporation Methods and compositions for treating and preventing distal bowel lesions
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
AR039165A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Venlafaxina base
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
ATE554752T1 (de) * 2004-02-06 2012-05-15 Pharmatel R & D Pty Ltd As Trustee For The Pharmatel R & D Trust Verwendung von aminosalicylaten beim reizdarmsyndrom mit durchfall als vorherrschendem symptom
NZ565974A (en) * 2005-08-24 2012-07-27 Salix Pharmaceuticals Ltd Balsalazide formulations and manufacture and use thereof
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
BRPI0622007A2 (pt) * 2006-09-13 2011-12-20 Procter & Gamble uso de aminossalicilato para tratar colite ulcerativa

Also Published As

Publication number Publication date
US20090252788A1 (en) 2009-10-08
JP2018145202A (ja) 2018-09-20
EP1931354A4 (en) 2010-03-24
JP2009506067A (ja) 2009-02-12
EP2586427A3 (en) 2013-05-29
WO2007025146A2 (en) 2007-03-01
CN102670626A (zh) 2012-09-19
MX2008002283A (es) 2008-09-08
NZ603744A (en) 2014-06-27
NZ565974A (en) 2012-07-27
BRPI0615195A8 (pt) 2018-03-06
CN101247812A (zh) 2008-08-20
CA2816276A1 (en) 2007-03-01
NZ593132A (en) 2013-02-22
BRPI0615195A2 (pt) 2011-05-10
WO2007025146A3 (en) 2007-07-12
EP1931354A2 (en) 2008-06-18
CA2620091A1 (en) 2007-03-01
JP2015108021A (ja) 2015-06-11
AU2006282865B2 (en) 2012-08-23
EP2586427A2 (en) 2013-05-01
CN105267226A (zh) 2016-01-27
JP2012246322A (ja) 2012-12-13
AU2006282865A1 (en) 2007-03-01
CN103948609A (zh) 2014-07-30
IL189104A (he) 2013-07-31
EP2529729A1 (en) 2012-12-05
IL189104A0 (en) 2008-08-07
US20160279153A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
IL225695A0 (he) תכשיר רוקחי המכיל בלסלאזיד או סודיום בלסלאזיד לשימוש בטיפול במחלות דרכי העיכול
IL251539A0 (he) צורת מינון רוקחית יחידה
EP1929990A4 (en) DRUG DONATION
IL182020A0 (en) Pharmaceutical composition comprising diclofenac
EP1898922A4 (en) MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
IL187220A (he) שימוש בנתרן מטא ארסניט בהכנת תרופה לטיפול במחלות גידוליות מטסטטיות
IL190787A0 (en) Agents that bind a target in pulmonary tissue for treating respiratory diseases
AP2008004533A0 (en) Pharmaceutical combination
IL177847A0 (en) Use of lipid conjugates in the treatment of disease
PL1957073T3 (pl) Substancja lecznicza
GB0526332D0 (en) Pharmaceutical product
ZA200803152B (en) Oramucosal pharmaceutical dosage form
IL212214A0 (en) Use of lipid conjugates in the treatment of disease
EP1871344A4 (en) INHIBITABLE MEDICINAL PRODUCT
ZA200804666B (en) Pharmaceutical combination
ZA200707910B (en) Contraceptive pharmaceutical preparation
GB0522473D0 (en) A pharmaceutical formulation
EP1864664A4 (en) PHARMACEUTICAL PREPARATION
IL190926A0 (en) A pharmaceutical composition containing a tissue protein
EP1716865A4 (en) PHARMACEUTICAL PREPARATION CONTAINING PARAOXONASE
GB0515137D0 (en) Product for use in surgery
GB0500826D0 (en) Pharmaceutical use
GB0515315D0 (en) Pharmaceutical agents
GB0515304D0 (en) Medicinal agents
HK1125634A1 (en) Pharmaceutical for use in the treatment of ureterolithiasis